



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

817, Bldg. No. 3, Navjivan Commercial Premises Co.-op. Soc., Lamington Rd., Mumbai Central (E), Mumbai - 400 008.
☎ : 2309 6121 • Mob. : 98926 40589 • E-mail : ca_mittal@rediffmail.com • nkmittalandassociates@gmail.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

LIMITED REVIEW REPORT FOR THE PERIOD ENDED 30.06.2014

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 30th June, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES
Chartered Accountants


N.K.MITTAL
(Proprietor)
M.No.46785
Place: Mumbai
Date: 12.08.2014



MARKSANS PHARMA LIMITED

Registered Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053 [CIN:L24110MH1992PLC066364]
 Corporate Office: Suite No. 8, Tower 3, Equinox Business Park, Off Bandra Kurla Complex, L.B.S. Marg, Mumbai - 400070
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2014

(₹ in Million)

Sr. No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		Quarter ended	Quarter ended	Quarter ended	Previous Year ended	Quarter ended	Quarter ended	Quarter ended	Previous Year ended
		30.06.2014 (UNAUDITED)	31.03.2014 (AUDITED)	30.06.2013 (UNAUDITED)	31.03.2014 (AUDITED)	30.06.2014 (UNAUDITED)	31.03.2014 (AUDITED)	30.06.2013 (UNAUDITED)	31.03.2014 (AUDITED)
1	Income								
	a) Net Sales/ Income from Operations (Net of excise duty)	1,006.65	836.70	720.21	3,149.45	1,588.63	1,410.31	6,299.97	
	b) Other Operating Income	-	6.08	27.04	33.12	7.32	27.22	35.04	
	Total Income from operations (net)	1,006.65	842.78	747.25	3,182.57	1,595.95	1,437.53	6,335.01	
2	Expenses								
	a) Cost of Material Consumed	448.93	483.04	246.35	1,426.34	620.05	431.39	2,290.47	
	b) Purchase of Stock - in- trade	84.10	67.31	78.21	288.37	417.38	342.11	1,416.54	
	c) Changes in Inventories of finished goods , work-in -progress and stock- in- trade	24.49	(14.19)	15.58	(18.41)	(23.51)	15.58	(27.72)	
	d) Employee benefits expense	58.20	71.24	46.81	213.89	163.50	151.80	664.41	
	e) Depreciation and amortisation expense	22.42	19.63	22.05	86.56	36.02	32.05	156.91	
	f) Other expenses	92.92	99.63	144.20	401.09	175.73	232.08	778.95	
	Total Expenses	731.06	726.66	553.20	2,397.84	1,389.17	1,205.01	5,279.56	
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	275.59	116.12	194.05	784.73	206.78	232.52	1,055.45	
4	Other Income	-	-	-	-	-	-	-	
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	275.59	116.12	194.05	784.73	206.78	232.52	1,055.45	
6	Finance cost	25.44	34.72	21.98	152.13	37.09	32.60	191.33	
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	250.15	81.40	172.07	632.60	169.69	199.92	864.12	
8	Exceptional items	-	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	250.15	81.40	172.07	632.60	169.69	199.92	864.12	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	67.51	28.52	4.20	77.02	60.31	8.28	127.87	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	182.64	52.88	167.87	555.58	109.38	191.64	736.25	
12	Less: Extraordinary item	-	-	-	-	-	-	-	
13	Net Profit/ (Loss) for the period (11-12)	182.64	52.88	167.87	555.58	109.38	191.64	736.25	
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	-	
15	Minority Interest	-	-	-	-	3.06	3.81	17.17	
16	Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)	182.64	52.88	167.87	555.58	106.32	187.83	719.08	
17	Paid up Equity Share Capital (Face Value Re.1 each)	385.31	385.31	385.31	385.31	385.31	385.31	385.31	
18	Reserve Excluding Revaluation Reserve	-	-	-	1,078.89	-	-	901.52	
19 a)	Earnings Per Share (before extraordinary items.-Rs.)- Basic	0.47	0.14	0.44	1.44	0.28	0.50	1.91	
	Diluted	0.47	0.14	0.44	1.44	0.28	0.50	1.91	
b)	Earnings Per Share(after extraordinary items.- Rs.)- Basic	0.47	0.14	0.44	1.44	0.28	0.49	1.87	
	Diluted	0.47	0.14	0.44	1.44	0.28	0.49	1.87	



(Handwritten signature)

PART 2		A PARTICULARS OF SHAREHOLDING							
1	Public Shareholding:								
	- Number of Shares	187,815,471	187,815,471	187,999,472	187,815,471	187,999,472	187,815,471	187,999,472	187,815,471
	- Percentage of Holding	48.75%	48.75%	48.79%	48.75%	48.79%	48.75%	48.79%	48.75%
2	Promoters and Promoter group Shareholdings	197,491,733	197,491,733	197,307,732	197,491,733	197,307,732	197,491,733	197,307,732	197,491,733
	a). Pledged/Encumbered								
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A
	b). Non-encumbered								
	- Number of Shares	197,491,733	197,491,733	197,307,732	197,491,733	197,307,732	197,491,733	197,307,732	197,491,733
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.25%	51.21%	51.25%	51.21%	51.25%	51.21%	51.25%

B INVESTOR COMPLAINTS		Quarter ended
	Pending at the beginning of the quarter	30.06.2014
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	-
		Nil

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.08.2014.
- 2 The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 3 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 4 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 5 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 6 The figure for the quarter ended March 31,2014 are the balancing figures between audited figures in respect of the full financial year ended March 31,2014 and the unaudited published year to date figure upto December 31,2013 being the date of the end of the third quarter of the previous financial year.
- 7 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.



For: MARKSANS PHARMA LIMITED

(Signature)
 MARK SALDANHA
 Managing Director.

Place: Mumbai.
 Date: 12.08.2014
www.marksanspharma.com